Vaxcyte, Inc. (PCVX), formerly known as SutroVax, Inc., is an innovative biotechnology company committed to the development and commercialization of vaccines that prevent infectious diseases. The company's mission is to develop transformative and life-saving vaccines to combat a variety of diseases globally.
Located in Foster City, California, the company was founded by Jeffrey Fairman and Puneet Dewan in 2013 with the vision to become a leading independent vaccine company. Vaxcyte specializes in conjugate vaccines and computational vaccinology, leveraging the latest advances in scientific research and technology.
The company's lead product candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) intended to prevent invasive pneumococcal disease (IPD) and pneumonia. It is developed to cover a broader range of disease-causing serotypes than the currently marketed vaccines. If approved, VAX-24 has the potential to become the leading pneumococcal vaccine in a multi-billion dollar market worldwide.
Vaxcyte (PCVX) went public in June 2020, making a high-profile entry into the biotech industry. Since then, the company has been dedicated to advancing their lead product VAX-24 through various clinical trials. At the same time, they have been working diligently on developing a dynamic pipeline of new vaccine candidates to protect against other infectious diseases.
Vaxcyte's innovative approach comprises of employing structure-based design along with high-throughput screening, biophysical characterization, and advanced animal models. This approach allows them to develop novel vaccines that elicit a strong and long-lasting immune response.
At the core of Vaxcyte's strategy is the conviction that the prevention of infectious diseases is more beneficial, cost-effective, and efficient than treatment. Since its inception, the company has focused on creating a meaningful and lasting impact by equipping individuals with the necessary defense development against illnesses, aiming for a healthier world.
The Company’s leadership team comprises seasoned industry veterans with a track record of developing and commercializing vaccines. Vaxcyte also holds a strong patent portfolio and has established key collaborations with multiple academic and research institutions, which further underline their commitment to creating innovative vaccines.
With a forward-thinking approach, Vaxcyte, Inc. (PCVX) continues to make strides in the vaccine development field and could potentially be a game-changer in the fight against infectious diseases worldwide. Their dedication to revolutionizing vaccine development demonstrates a fundamental commitment to global health, making it an ambitious player in the biotech industry.